RecruitingAlzheimer Disease
A Study of AMDX-2011P in Participants With Alzheimer's Disease
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).
Sponsor: Amydis Inc.
You may qualify if…
- ✓ 1. Confirmed diagnosis of Alzheimer's Disease (AD) with documented positive amyloid beta signal via positron emission tomography (PET) brain scan
- ✓ 2. Must be willing to consent to genotyping for apolipoprotein E (APOE)
- ✓ 3. Ability to fixate and undergo retinal imaging of both eyes
You may not qualify if…
- ✕ 1. Presence of any underlying physical or psychological medical condition that, in the opinion of the investigator, would make it unlikely that the participant will complete the study per protocol
- ✕ 2. Diagnosis of glaucoma, or suspect of having glaucoma in either eye as determined by an ophthalmologist as a clinical investigator, based on results from the eye examination, visual field, and/or optical coherence tomography (OCT) results
- ✕ 3. Diagnosis of intermediate dry, wet/neovascular, or geographic atrophy forms of age-related macular degeneration (AMD) in either eye, OR as determined by an ophthalmologist as a clinical investigator, based on results from the eye examination and/or optical coherence tomography (OCT) results
- ✕ 4. Clinically significant laboratory abnormalities as assessed by the investigator
- ✕ 5. Prolonged QTcF (corrected QT interval by Fridericia method) (\>450 ms for males and \>470 ms for females), cardiac arrhythmia, or any clinically significant abnormality in the resting electrocardiogram (ECG), as judged by the investigator.
Where it's recruiting
Arizona
Phoenix
Source: ClinicalTrials.gov · NCT06514001 · last updated 2026-08-31